Stellate Ganglion Block (SGB) For Women for Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact
their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic
women with breast cancer who are on anti-estrogens and are seeking relief from moderate to
very severe VMS that are adversely affecting health and wellbeing. Women with breast cancer
on Tamoxifen, aromatase inhibitors (AIs) or Selective Estrogen Receptor Modulators (SERMS)
with moderate to very severe VMS will be enrolled as participants in this study.